December 8, 2020
The Proven Model for Improving Clinical Trial Results During the Pandemic
The pharmaceutical industry has not escaped the impact of the COVID-19 crisis. Every phase of…
Read More
November 23, 2020
How to Build an Integrated Service Model for Rare and Orphan Drugs
Six Questions You Should Ask a Consultant Many drug manufacturers and healthcare consultants attempt to…
Read More
October 16, 2020
9 Steps to Improving Patient Access to Rare and Orphan Drugs
A conversation on eHealth Radio Recently, I had the privilege of a thought-provoking conversation on…
Read More
September 22, 2020
How to Stay Focused on Rare and Orphan Disorders in the Time of COVID
4 Critical Success Factors for Manufacturers Before I became president and CEO of Optime Care,…
Read More
August 20, 2020
Product First Means Patients Left Behind
A tale of too many patients. My family has a long history of alpha-1 antitrypsin…
Read More
July 13, 2020
Scale vs. Service? Your rare drug demands both.
When developing a drug commercialization strategy, there’s a misconception that patient service and program scalability are mutually exclusive. The prevailing…
Read More
June 18, 2020
Revealing 5 hidden truths about using a hub-and-spoke model for rare and orphan drugs
The hub-and-spoke approach has become a standard of drug commercialization. Having a network of patient…
Read More
June 16, 2020
Debunking 6 Myths About Gaining Payer Access for Rare and Orphan Drugs
What works for large patient populations isn’t necessarily a good fit for those with rare…
Read More
Rare Voices Podcast
- S1E4: Bill Jollie, Global Pharmaceutical September 24, 2020
- S1E3: Ken Greathouse, serial entrepreneur and philanthropist July 7, 2020
- S1E2: Jim Clement, Coues Consulting July 7, 2020